title: Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants.
abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease with predominant joint involvement and possible systemic compromise, which leads to a handicapped status and poor quality of life. An optimal approach to treat RA requires early and intensive intervention with close monitoring of treatment response. Tumor necrosis factor (TNF) blockers are recommended in cases of active RA after the unsuccessful use of effective disease-modifying antirheumatic drugs (DMARDs); even adding them to treatment or replacing these drugs. Anti-TNF therapies have been demonstrated to reduce significant joint damage and to relieve symptoms during a prolonged time (see Scott and Kingsley, 2006). The efficacy of infliximab in an open-label trial is summarized with respect to speed of onset of action, durability of response, and its correlation between clinical and laboratory parameters. Safety for long-term treatment is also summarized. We studied 105 RA patients with more than 3 years' history of disease during 24 months on i.v. infliximab (75 completed study). We evaluated ACR responses at base line, and at 1, 6, 12, 16, 52, 77, and 104 weeks. Morning stiffness, swollen and tender joints, HAQ, SF-36% (PCS/MCS), polymerase chain reaction (PCR), erythrosedimentation rate (ESR), transaminases, rheumatoid factor (RF) levels, hemogram, and adverse events profile were all assessed. The treatment offered rapid and sustained clinical improvements as revealed by ACR responses and marked changes in the parameters previously described. Important changes were made in functional status and acute-phase reactants. Finally, infliximab was considered well tolerated and did not affect the safety profile of this trial.
authors.affiliation: Rheumatology, Autoimmune and Metabolic Bone Diseases Unit, Durand Hospital, 5044 Diaz Velez Avenue, 1405, Buenos Aires, Argentina. hdreuma@intramed.net
authors.forename: J J
authors.initials: JJ
authors.lastname: Scali
authors.forename: S
authors.initials: S
authors.lastname: Visentini
authors.forename: J
authors.initials: J
authors.lastname: Salomón
authors.forename: D
authors.initials: D
authors.lastname: Sevilla
authors.forename: Y C
authors.initials: YC
authors.lastname: Ju
authors.forename: E
authors.initials: E
authors.lastname: Morales
authors.forename: L
authors.initials: L
authors.lastname: Ugarte
authors.forename: A
authors.initials: A
authors.lastname: Tachdjian
authors.forename: G
authors.initials: G
authors.lastname: Pacheco
authors.forename: S
authors.initials: S
authors.lastname: Veiga
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology* / Q000473:pathology; D005260:Female; D006262:Health; D006801:Humans; D007167:Immunotherapy; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000276:immunology; D011795:Surveys and Questionnaires; D013997:Time Factors; D000637:Transaminases / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab; D000637:Transaminases